Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies

Katalin Balassa, H. Andrikovics, Peter Remenyi, Arpad Batai, Aniko Szilvasi, Andras Bors, Katalin Piroska Kiss, K. Rajczy, Dora Inotai, Eva Torbagyi, Lilla Lengyel, Aniko Barta, Laszlo Gopcsa, A. Tordai, T. Masszi

Research output: Article

Abstract

The role of HLA system in allogeneic haematopoietic stem cell transplantation (allo-HSCT) outcome is unarguable. In this study we investigated association of HLA-A,-B and-DRB1 alleles with overall survival (OS) in 186 patients undergoing allo-HSCT for lymphoid malignancies. Analyses confirmed significantly better OS for HLA-DRB1∗04 carriers compared with non-carriers (p = 0.01). Survival benefit was confined to male patients (in multivariate analyses p = 0.034, hazard ratio 0.35, 95% confidence interval 0.13–0.92), whereas in females no difference was noted (p = 0.82). Furthermore, donor gender also affected outcome and transplantation from female HLA-DRB1∗04 carrier donors resulted in superior survival compared with female non-carrier donors (p = 0.01). Combined analyses including recipient/donor gender and HLA-DRB1∗04 showed that survival of male patients varied significantly according to donor gender and HLA-DRB1∗04 carriership (p = 0.04) with best survival among HLA-DRB1∗04 carriers transplanted from female donors. Of relevance to our results, HLA-DRB1∗04 has been documented as risk allele group for lymphoid malignancies, and studies described a male-specific risk. We believe that our findings provide further supporting evidence for sex-specific alterations secondary to HLA-DRB1∗04 or related genes. Further studies are warranted to evaluate whether in contrast to general favour of male donors HLA-DRB1∗04 carrier patients with lymphoid malignancies could benefit from transplantation from female donors.

Original languageEnglish
Pages (from-to)13-19
Number of pages7
JournalHuman Immunology
Volume79
Issue number1
DOIs
Publication statusPublished - jan. 1 2018

Fingerprint

Hematopoietic Stem Cell Transplantation
Tissue Donors
Survival
Neoplasms
Transplantation
Alleles
HLA-A Antigens
HLA-B Antigens
Multivariate Analysis
Confidence Intervals
Genes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies. / Balassa, Katalin; Andrikovics, H.; Remenyi, Peter; Batai, Arpad; Szilvasi, Aniko; Bors, Andras; Kiss, Katalin Piroska; Rajczy, K.; Inotai, Dora; Torbagyi, Eva; Lengyel, Lilla; Barta, Aniko; Gopcsa, Laszlo; Tordai, A.; Masszi, T.

In: Human Immunology, Vol. 79, No. 1, 01.01.2018, p. 13-19.

Research output: Article

Balassa, Katalin ; Andrikovics, H. ; Remenyi, Peter ; Batai, Arpad ; Szilvasi, Aniko ; Bors, Andras ; Kiss, Katalin Piroska ; Rajczy, K. ; Inotai, Dora ; Torbagyi, Eva ; Lengyel, Lilla ; Barta, Aniko ; Gopcsa, Laszlo ; Tordai, A. ; Masszi, T. / Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies. In: Human Immunology. 2018 ; Vol. 79, No. 1. pp. 13-19.
@article{68c4f1bb211a4baebd5f5fb987e78a27,
title = "Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies",
abstract = "The role of HLA system in allogeneic haematopoietic stem cell transplantation (allo-HSCT) outcome is unarguable. In this study we investigated association of HLA-A,-B and-DRB1 alleles with overall survival (OS) in 186 patients undergoing allo-HSCT for lymphoid malignancies. Analyses confirmed significantly better OS for HLA-DRB1∗04 carriers compared with non-carriers (p = 0.01). Survival benefit was confined to male patients (in multivariate analyses p = 0.034, hazard ratio 0.35, 95{\%} confidence interval 0.13–0.92), whereas in females no difference was noted (p = 0.82). Furthermore, donor gender also affected outcome and transplantation from female HLA-DRB1∗04 carrier donors resulted in superior survival compared with female non-carrier donors (p = 0.01). Combined analyses including recipient/donor gender and HLA-DRB1∗04 showed that survival of male patients varied significantly according to donor gender and HLA-DRB1∗04 carriership (p = 0.04) with best survival among HLA-DRB1∗04 carriers transplanted from female donors. Of relevance to our results, HLA-DRB1∗04 has been documented as risk allele group for lymphoid malignancies, and studies described a male-specific risk. We believe that our findings provide further supporting evidence for sex-specific alterations secondary to HLA-DRB1∗04 or related genes. Further studies are warranted to evaluate whether in contrast to general favour of male donors HLA-DRB1∗04 carrier patients with lymphoid malignancies could benefit from transplantation from female donors.",
keywords = "Allogeneic HSCT, HLA allele groups, HLA-DRB1∗04, Lymphoid malignancy, Survival",
author = "Katalin Balassa and H. Andrikovics and Peter Remenyi and Arpad Batai and Aniko Szilvasi and Andras Bors and Kiss, {Katalin Piroska} and K. Rajczy and Dora Inotai and Eva Torbagyi and Lilla Lengyel and Aniko Barta and Laszlo Gopcsa and A. Tordai and T. Masszi",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.humimm.2017.10.010",
language = "English",
volume = "79",
pages = "13--19",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies

AU - Balassa, Katalin

AU - Andrikovics, H.

AU - Remenyi, Peter

AU - Batai, Arpad

AU - Szilvasi, Aniko

AU - Bors, Andras

AU - Kiss, Katalin Piroska

AU - Rajczy, K.

AU - Inotai, Dora

AU - Torbagyi, Eva

AU - Lengyel, Lilla

AU - Barta, Aniko

AU - Gopcsa, Laszlo

AU - Tordai, A.

AU - Masszi, T.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The role of HLA system in allogeneic haematopoietic stem cell transplantation (allo-HSCT) outcome is unarguable. In this study we investigated association of HLA-A,-B and-DRB1 alleles with overall survival (OS) in 186 patients undergoing allo-HSCT for lymphoid malignancies. Analyses confirmed significantly better OS for HLA-DRB1∗04 carriers compared with non-carriers (p = 0.01). Survival benefit was confined to male patients (in multivariate analyses p = 0.034, hazard ratio 0.35, 95% confidence interval 0.13–0.92), whereas in females no difference was noted (p = 0.82). Furthermore, donor gender also affected outcome and transplantation from female HLA-DRB1∗04 carrier donors resulted in superior survival compared with female non-carrier donors (p = 0.01). Combined analyses including recipient/donor gender and HLA-DRB1∗04 showed that survival of male patients varied significantly according to donor gender and HLA-DRB1∗04 carriership (p = 0.04) with best survival among HLA-DRB1∗04 carriers transplanted from female donors. Of relevance to our results, HLA-DRB1∗04 has been documented as risk allele group for lymphoid malignancies, and studies described a male-specific risk. We believe that our findings provide further supporting evidence for sex-specific alterations secondary to HLA-DRB1∗04 or related genes. Further studies are warranted to evaluate whether in contrast to general favour of male donors HLA-DRB1∗04 carrier patients with lymphoid malignancies could benefit from transplantation from female donors.

AB - The role of HLA system in allogeneic haematopoietic stem cell transplantation (allo-HSCT) outcome is unarguable. In this study we investigated association of HLA-A,-B and-DRB1 alleles with overall survival (OS) in 186 patients undergoing allo-HSCT for lymphoid malignancies. Analyses confirmed significantly better OS for HLA-DRB1∗04 carriers compared with non-carriers (p = 0.01). Survival benefit was confined to male patients (in multivariate analyses p = 0.034, hazard ratio 0.35, 95% confidence interval 0.13–0.92), whereas in females no difference was noted (p = 0.82). Furthermore, donor gender also affected outcome and transplantation from female HLA-DRB1∗04 carrier donors resulted in superior survival compared with female non-carrier donors (p = 0.01). Combined analyses including recipient/donor gender and HLA-DRB1∗04 showed that survival of male patients varied significantly according to donor gender and HLA-DRB1∗04 carriership (p = 0.04) with best survival among HLA-DRB1∗04 carriers transplanted from female donors. Of relevance to our results, HLA-DRB1∗04 has been documented as risk allele group for lymphoid malignancies, and studies described a male-specific risk. We believe that our findings provide further supporting evidence for sex-specific alterations secondary to HLA-DRB1∗04 or related genes. Further studies are warranted to evaluate whether in contrast to general favour of male donors HLA-DRB1∗04 carrier patients with lymphoid malignancies could benefit from transplantation from female donors.

KW - Allogeneic HSCT

KW - HLA allele groups

KW - HLA-DRB1∗04

KW - Lymphoid malignancy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85032738065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032738065&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2017.10.010

DO - 10.1016/j.humimm.2017.10.010

M3 - Article

C2 - 29080718

AN - SCOPUS:85032738065

VL - 79

SP - 13

EP - 19

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 1

ER -